ClinicalTrials.gg
Active, not recruitingNCT06023680STARTUpdated Oct 5, 2026

The Sedentary to Active Rising to Thrive (START) Trial

An interventional study of Continuous sedentary reduction intervention and Bouted sedentary reduction intervention in Sedentary Time and Frailty, sponsored by Johns Hopkins Bloomberg School of Public Health. Active, not recruiting at 2 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Johns Hopkins Bloomberg School of Public Health · Not applicable, Interventional, and Other

How we know

Updated Oct 5, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 452 studies in Sedentary Behavior with a site in United States — 61 open to participants now, 89 under way, none of them phase 3. Sedentary Behavior · United States.

Enrollment
192nd of 421
61 · median 60
Started
2023
with 44 others
No phase
386 of 452
54 open now
Primary completion
2026-07
later than 18 of 88 live
Registered
364th of 452
by date

Among the 452 studies in Sedentary Behavior with a site in United States, this one is the 192nd largest by enrollment of the 421 interventional ones that give a count, is one of 45 that started in 2023, is one of 386 with no phase, reaches primary completion later than 18 of the 88 other live ones, and was the 364th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

61 of the 452 studies in Sedentary Behavior with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 452 studies in Sedentary Behavior with a site in United States, or all of them as a file.
02

Study summary

The goal of this behavioral clinical trial is to compare two different ways of becoming less sedentary and more active in 60 older adults at elevated risk of becoming frail.

The main question this project aims to answer are whether participants in each intervention are able to gradually replace 30 minutes of sedentary (sitting-like) behavior with very light walking over 60 days.

There are other questions this project aims to answer that include:

  1. whether it is easier to replace sedentary behavior with one 30-minute walking bout or three 10-minute walking bouts
  2. whether becoming less sedentary and more active leads to feeling better, have less stress, pain, and fatigue and have more confidence in becoming more regularly active
  3. whether becoming less sedentary and more active leads to better regulation of inflammation and metabolism

Participants will be randomized into one of two sedentary reduction behavior programs; one program that gradually replaces sedentary time with one 30-minute walking bout and the other program that gradually replaces sedentary time with three 10-minute walking bouts in the morning, afternoon, and evening. Researchers will compare both programs to see which one is easier to achieve and maintain over 60 days.

Read the detailed description

Initiating and maintaining habitual physical activity is difficult for sedentary older adults, particularly those encumbered by health challenges. The 2018 US Physical Activity Guidelines recommends that all adults perform ≥150 minutes/week of physical activity and reduce sedentary behaviors. Yet, traditional approaches to increase physical activity do little to address sedentary behavior reduction, especially for older adults. Lower sedentary behavior is associated with improved biological and psychosocial health-independent of meeting physical activity guidelines. Thus, there remains a critical need to implement and evaluate a structured way to reduce sedentary behavior as a potential pathway for habitual physical activity engagement.

This project aims to test two prescribe-able and feasible strategies to initiate and incorporate sedentary behavior reduction into daily lifestyle with remote monitoring. The interventions are an inexpensive and low burden approach to reduce sedentary behavior and promote habitual physical activity. Moreover, accelerometer-based outcomes of sedentary behavior are novel in intervention settings, particularly when measured in free-living, real-world settings. Lastly, this project directly addresses a gap of successful remotely deployable interventions geared to initiate and build activity into daily life by replacing sedentary time among older adults.

Aim 1. Explore the effectiveness of 2 interventions to reduce sedentary time in pre-frail older adults over 2 months

Hypothesis 1a. Each intervention will reduce objectively measured daily sedentary time from baseline levels over 2 months.

Hypothesis 1b. The continuous intervention will result in more reduction of objectively measured sedentary time than the bouts intervention.

Aim 2. Explore the dose-response relationship between sedentary time changes and patient-reported outcomes that include fatigue, fatigability, anxiety, general and exercise-based self-efficacy, stress, pain, and mood over 2 months

Hypothesis 2: Decreased daily sedentary time over 2 months is associated with decreased fatigue, fatigability, anxiety, stress, and pain, and increased general and exercise-based self-efficacy and mood over 2 months.

Aim 3. Explore the dose-response relationship between sedentary time changes and biomarkers of frailty-related inflammation, including serum interleukin (IL-6) (pg/mL) and tumor necrosis factor (TNF) -alpha receptor 1 (pg/mL) over 2 months

Hypothesis 3. Decreased daily sedentary time is associated with decreased serum (IL-6) and TNF-alpha receptor 1 over 2 months.

Aim 4. Explore the dose-response relationship between changes in sedentary time with biomarkers of glucose and lipid metabolism (glucose, insulin, total cholesterol (TC), low-density lipoprotein cholesterol (LDLC), triglycerides, high-density lipoprotein cholesterol (HDLC)), a cytokine marker related to frailty (Growth/Differentiation Factor-15; (GDF-15), hemoglobin A1C (hbA1c), non-esterified free fatty acid, and untargeted metabolomics-based markers of energy regulation.

Hypothesis 4. Decreased daily sedentary time is associated with decreased levels of blood glucose, insulin, TC, LDLC, triglycerides and increased HDLC, decreased GDF-15, decreased hbA1c, decreased non-esterified free fatty acid, and lower circulating metabolites necessary for energy regulation over 2 months.

Aim 5. Explore the dose-response and diurnal relationships between changes in sedentary time and interstitial glucose continuously monitored over 24 hours for 14 consecutive days using a Libre Pro sensor at baseline and 2 months later

Hypothesis 5. Decreased sedentary time is associated with decreased overall glucose and different time-of-day glucose levels, coefficient of variation, % of time in glucose at various ranges (e.g., ≥200, ≥180, ≥140, 70-180, 70-140, \<70, \<54 mg/dL), mean daily difference, and mean amplitude of glycemic excursion) over 2 months.

03

Conditions studied

  • Sedentary Time
  • Frailty

Keywords

  • Physical Activity
  • Walking
  • Older Adults
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥65 years
  • Pre-frail defined as having 1-2 of the following criteria:
  • Self-reported unintentional weight loss
  • Self-reported fatigue
  • Self-reported low activity
  • Slowness measured during a 4-m walking test
  • Weakness measured with grip strength
  • Self-reported regular physical activity \<20 minutes/day
  • Self-reported willingness to work up to walking for 30 minutes/day
  • Self-reported ability to find a place to walk for up to 30 minutes/day
  • Agree to all study procedures and assessments
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Self-reported diabetes
  • Self-reported problems related to alcohol or drugs
  • Self-reported inability to walk across a room
  • Self-reported use of a walker
  • Self-reported requirement of medical supervision when engaging in physical activity
  • Fallen >2 times in the past month
  • Participation in another clinical trial
  • Plan to move out of the area within 6 months
  • Inability to provide self-transportation to study assessment visits
  • Inability to complete a usual-paced 400m walking test within 15 minutes without sitting or the help of another
  • Uncontrolled resting hypertension (>160/90 mmHg)
  • Cognitive impairment determined using the Test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
61 participants (actual)

Study arms

  • Active comparator
    Continuous sedentary reduction intervention

    Structured intervention to progressively replace sedentary time with one daily 30-minute light-intensity walking bout

    Behavioral: Continuous sedentary reduction intervention

  • Active comparator
    Bouted sedentary reduction intervention

    Structured intervention to progressively replace sedentary time with three daily 10-minute light-intensity walking bouts

    Behavioral: Bouted sedentary reduction intervention

Interventions

  • BehavioralContinuous sedentary reduction intervention

    During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts). During Phase 2, the three 10-minute walking bouts will be gradually combined into one 30-minute bout over the course of 20 days.

  • BehavioralBouted sedentary reduction intervention

    During Phase 1, one minute of sedentary time will be replaced with very light to light intensity walking at three different times during the day, every day for 10 days, reaching three separate 10-minute walking intervals (or bouts). During Phase 2, the three 10-minute walking bouts will be maintained over the course of 20 days.

06

What researchers measure

Primary outcomes

  1. Change in Sedentary Time

    Sedentary time measured with a wrist worn monitor containing an accelerometer sensor This measurement is collected under a 7-day/24-hour wear protocol at baseline and again 2 months afterwards to determine the change in sedentary time before and after either intervention.

    Time frame: Baseline, 2 months

  2. Intervention Difference in the Change in Sedentary Time

    Comparing the 2-month change in sedentary time between the two interventions

    Time frame: Baseline, 2 months

Secondary outcomes

  1. Change in Physical Activity Accumulation

    Physical activity fragmentation (e.g., broken up activity accumulation) wrist worn monitor containing an accelerometer sensor

    Time frame: Baseline, 2 months

  2. Change in Walking Ability

    Ability to walk measured at a usual walking pace for 400m at baseline and 2 months afterwards.

    Time frame: Baseline, 2 months

  3. Change in Walking Speed

    Walking speed measured at a usual walking pace for 4m at baseline and 2 months afterwards.

    Time frame: Baseline, 2 months

  4. Change in Fatigue

    Fatigue measured using a Fatigue Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-13 where higher scores mean higher fatigue.

    Time frame: Baseline, 2 months

  5. Change in Fatigability

    Fatigability measured using a Pittsburgh Fatigability questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-100 where higher scores mean higher fatigability.

    Time frame: Baseline, 2 months

  6. Change in Anxiety

    Anxiety measured using an Anxiety Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-20 where higher scores mean higher anxiety.

    Time frame: Baseline, 2 months

  7. Change in General Self Efficacy

    General Self Efficacy measured using a General Self Efficacy questionnaire measured at baseline and 2 months afterwards On the questionnaire, a score can range from 0-50 where higher scores mean higher general self efficacy.

    Time frame: Baseline, 2 months

  8. Change in Exercise-based Self Efficacy

    Exercise-based Self Efficacy measured using an Exercise-based Self Efficacy questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-90 where higher scores mean higher exercise-based self efficacy.

    Time frame: Baseline, 2 months

  9. Change in Stress

    Stress measured using a Perceived Stress Scale questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-70 where higher scores mean higher stress.

    Time frame: Baseline, 2 months

  10. Change in Pain

    Pain measured using a modified version of the McGill pain questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-5 where higher scores mean greater pain.

    Time frame: Baseline, 2 months

  11. Change in Mood

    Mood measured using a Profile of Mood Status questionnaire measured at baseline and 2 months afterwards. On the questionnaire, a score can range from 0-20 where higher scores mean greater mood disturbance.

    Time frame: Baseline, 2 months

  12. Change in Inflammation

    Inflammation measured from blood draws quantifying serum IL-6 (pg/mL) and TNF-alpha receptor 1 (pg/mL) at baseline and 2 months afterwards

    Time frame: Baseline, 2 months

  13. Change in Blood Glucose

    Blood glucose measured from blood draws

    Time frame: Baseline, 2 months

  14. Change in Insulin

    Insulin measured from blood draws

    Time frame: Baseline, 2 months

  15. Change in Total Cholesterol

    Total cholesterol measured from blood draws

    Time frame: Baseline, 2 months

  16. Change in Low-Density Lipoprotein Cholesterol

    Low-density lipoprotein cholesterol measured from blood draws

    Time frame: Baseline, 2 months

  17. Change in High-Density Lipoprotein Cholesterol

    High-density lipoprotein cholesterol measured from blood draws

    Time frame: Baseline, 2 months

  18. Change in Triglycerides

    Triglycerides measured from blood draws

    Time frame: Baseline, 2 months

  19. Change in Growth/Differentiation Factor-15

    Growth/Differentiation Factor-15 measured from blood draws

    Time frame: Baseline, 2 months

  20. Change in Metabolites

    Untargeted metabolomics-based markers of energy regulation measured from blood draws

    Time frame: Baseline, 2 months

  21. Change in Hemoglobin A1c

    Hemoglobin A1c measured from blood draws

    Time frame: Baseline, 2 months

  22. Change in Non-Esterified Free Fatty Acid

    Non-Esterified Free Fatty Acid measured from blood draws

    Time frame: Baseline, 2 months

  23. Change in Interstitial Glucose

    Interstitial glucose measured using a continuous glucose monitor worn 24-hours each day for 14 consecutive days at baseline and 2 months afterwards. Specific measurements include overall glucose and different time-of-day glucose levels, coefficient of variation, % of time in glucose at various ranges (e.g., ≥200, ≥180, ≥140, 70-180, 70-140, \<70, \<54 mg/dL), mean daily difference, and mean amplitude of glycemic excursion).

    Time frame: Baseline, 2 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jul 2026, 31 months.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 31 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Primary completion moved twice since we started tracking on Sep 25, 2026: Nov 2025 → Jul 2026, last on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 5, 2023
StartActual
Nov 28, 2023
Primary completionActual
Jul 15, 2026was Nov 2025
CompletionEst.
Jun 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 4, 2025→Jul 15, 2026
moved 2 times, Sep 25, 2026 – Oct 5, 2026
Show all 2 updates
  1. Oct 5, 2026
    Primary completion Jul 14, 2026→Jul 15, 2026
    + 1 other change: verification date
  2. Sep 25, 2026
    Primary completion Nov 4, 2025→Jul 14, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06023680
Responsible party
Sponsor
First posted
Sep 5, 2023
Start date
Nov 28, 2023
Primary completion
Jul 15, 2026
Completion
Jun 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Amal Wanigatunga, PhD
principal investigator · Johns Hopkins Blomberg School of Public Health

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion